{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P35354",
      "entity_text" : "COX-2",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:5090",
      "entity_text" : "rofecoxib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "COX-2 selective inhibitors (CSIs) including rofecoxib have a 50% reduced risk of upper gastrointestinal toxicity, compared to nonselective inhibitors such as naproxen [XREF_BIBR, XREF_BIBR].",
  "reading_complete" : "2020-08-08T12:07:12Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T12:05:07Z",
  "trigger" : "inhibitors",
  "evidence" : [ "COX-2 selective inhibitors (CSIs) including rofecoxib" ],
  "pmc_id" : "4020456",
  "score" : 0
}